7.31
-0.0826(-1.12%)
Currency In USD
| Previous Close | 7.39 |
| Open | 7.3 |
| Day High | 7.51 |
| Day Low | 7.08 |
| 52-Week High | 13.79 |
| 52-Week Low | 4.56 |
| Volume | 2,021 |
| Average Volume | 7,991 |
| Market Cap | 29.12M |
| PE | -2.97 |
| EPS | -2.46 |
| Moving Average 50 Days | 7.36 |
| Moving Average 200 Days | 7.71 |
| Change | -0.08 |
If you invested $1000 in MiNK Therapeutics, Inc. (INKT) since IPO date, it would be worth $60.88 as of July 01, 2025 at a share price of $7.305. Whereas If you bought $1000 worth of MiNK Therapeutics, Inc. (INKT) shares 3 years ago, it would be worth $521.79 as of July 01, 2025 at a share price of $7.305.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
GlobeNewswire Inc.
Jun 10, 2025 5:33 PM GMT
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Sh
MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
GlobeNewswire Inc.
Jun 02, 2025 1:29 PM GMT
Non-dilutive NIH funding supports development of MiNK’s allogeneic iNKT platform for immune regulation in high-risk HSCT settingsNEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
GlobeNewswire Inc.
May 05, 2025 4:30 PM GMT
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNK